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showing residual disease on FDG-CT-PET scan 70 days post-treat-
ment, were studied. The volume of residual disease was deﬁned by the 
area with a Standardized Uptake Value (SUV) higher than mediastinal 
uptake. Overlap fractions (OF) were calculated between this residual 
disease volume and the original tumor, with several SUV threshold 
based auto-delineations on a FDG-CT-PET scan before radiotherapy.
2. Stability of the high FDG-uptake areas during radiotherapy. Twenty-
three patients underwent repeated FDG-CT-PET scans before and one 
and two weeks after the start of radiotherapy. Tumors with volumes 
>70 cm3 (n=9) were used to assess heterogeneity in FDG-uptake. OF’s 
were used to demonstrate the stability of the high FDG uptake regions 
(50% SUV volume) during treatment.
Results: 1. Location of residual disease within the tumor. The loca-
tion of the residual disease was nearly completely (OF > 95%) within 
the contour of the original tumor, deﬁned as the 34% threshold SUV 
contour, based on the source-to-background ratio (van Baardwijk et al 
Int J Radiat Oncol Biol Phys, 2007). As depicted in ﬁgure 1, on aver-
age (bold black line) the residual had an OF of more than 80% with 
the 50% threshold of the pre-treatment PET scan. This indicates that 
residual disease occurs within the high-uptake region of the original 
tumor and therefore, escalating dose to this speciﬁc area is likely to 
improve local control.
Figure 1. Overlap Fractions of the residual tumor with the SUV threshold of 
the PET scan before radiotherapy.
2. Stability of the high FDG-uptake areas during radiotherapy The 
mean OF’s of the high uptake zone during therapy were 75.7 ± 10.9% 
at day 7 and 67.5 ± 16.4% at day 14 during treatment. So, the loca-
tion of the high FDG uptake region within the tumor during treatment 
remained the same. 
Conclusions: Residual disease within the primary tumor is not due to 
geographic miss. The location of residual disease corresponds with the 
original 50% highest FDG uptake before radiotherapy.
This location of the high FDG uptake within the tumor remained stable 
during radiotherapy. Boosting of tumor sub-volumes may thus be 
feasible and potentially beneﬁcial, using only a FDG-PET scan before 
therapy.
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Background: Adjuvant and neoadjuvant chemotherapy play a role in 
optimising long-term outcome of patients with resectable non-small-
cell lung cancer (NSCLC). The epidermal growth factor receptor 
(EGFR) is a receptor tyrosine kinase that is overexpressed in NSCLC. 
Cetuximab, a monoclonal antibody, targets the extracellular domain 
of the EGFR preventing ligand binding. Preclinical data and phase II 
evidence in advanced NSCLC suggest that cetuximab potentiates the 
activity of conventional cytotoxic agents.
Methods: Patients with histologically conﬁrmed resectable stage 
IB-IIIA NSCLC and adequate end-organ function, giving informed 
written consent were eligible. Patients received 3-weekly cycles of 
cisplatin 80mg/m2 d1, gemcitabine 1250mg/m2 d1 & d8 and cetuximab 
400mg/m2 loading dose, thereafter weekly 250mg/m2. The primary 
endpoint is response rate (radiological and pathological). Secondary 
endpoints are safety and tolerability of the combination, resection rate 
following therapy, overall survival and relapse free survival. In addition 
serum, plasma and white blood cells are being collected before, during 
and after therapy from all patients. For proteomic analysis undenatured 
and unfractionated pretreatment serum samples underwent Surface 
Enhanced Laser Desorption/Ionisation Time of Flight Mass Spec-
trometry (SELDI-TOF MS) proﬁling using a strong anion exchange 
ProteinChip® array (Q10 Array).
Results: 30 patients have been recruited to date (19 men, 11 women), 
median age 64 (range 29-77), 24 patients stage I, 2 patients stage II, 4 
patients stage III. 27 patients have completed treatment and are evalu-
able for response. The overall response rate is 76% including CR - 1 
patient, PR -18 patients, SD -7 patients, PD -1 patient. The most com-
mon toxicity was skin rash (100%). The commonest grade 3/4 toxicities 
were neutropenia (52%) and thrombocytopenia (36%). There were 3 
grade 3 and 4 grade 4 cardiovascular toxicities in patients with signiﬁ-
cant co-morbid cardiovascular toxicities including peripheral arterial 
ischemia (2), cerebrovascular accident (3) and myocardial infarction 
(2). One patient was withdrawn from study because of complicated pe-
ripheral ischemia. Using ciphergen express software serum proteomic 
analysis in 21 patients divided into two groups -radiological responders 
vs non-responders - revealed six differentially expressed peaks.
Conclusions: The response rate appears higher then that reported for 
neoadjuvant chemotherapy in other studies. Patient accrual continues. 
Ongoing biomarker studies may identify those patients most likely 
to beneﬁt from induction treatment. In order to maximise the protein 
peaks we have depleted our samples of IgG and Albumin. We are 
currently proﬁling these denatured and depleted samples on three 
ProteinChip® arrays. 
